Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon added to index

Cephalon added to index

18th November 2008

Cephalon has been added to the Standard and Poor’s (S&P) 500 Index, it has confirmed.

The Pennsylvania-based company was included in the S&P MidCap 400 Index after the close of trading on November 14th.

Frank Baldino, chairman and chief executive of Cephalon – an international biopharmaceutical company – said it was “honoured” to be recognised as a major US company.

“This distinction is a result of the talented and dedicated employees,” he added.

“Over the past 21 years, we have built an enduring, diversified company and we are very proud of the fact that our products have helped millions of patients around the world.”

Founded more than two decades ago, Cephalon focuses on the discovery, development and commercialisation of innovative products in four core therapeutic areas – the central nervous system, pain, oncology and addiction.

It was already a member of the Fortune 1000 and has a workforce of around 3,000 people in the US and Europe.

Earlier in 2008 it was awarded the AmerisourceBergen Manufacturer of the Year accolade for the second consecutive year.

The S&P 500 Index – a respected gauge of the US equities market, according to Cephalon – includes 500 leading companies in chief industries of the US economy.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.